Akari Therapeutics (AKTX) Accumulated Depreciation & Amortization (2011 - 2020)

Akari Therapeutics has disclosed Accumulated Depreciation & Amortization across 7 years of filings, most recently posting $164938.0 for Q4 2020.

• Accumulated Depreciation & Amortization for Q4 2020 came in at $164938.0, up 3.13% year-over-year; the trailing twelve-month figure through Dec 2020 was $164938.0 (up 3.13% YoY), and the FY2020 annual result was $164938.0, up 3.13% from the prior year.
• Accumulated Depreciation & Amortization came in at $164938.0 for Q4 2020 at Akari Therapeutics, up from $159925.0 in the prior quarter.
• In the past five years, Accumulated Depreciation & Amortization ranged from a high of $164938.0 in Q4 2020 to a low of $144513.0 in Q4 2018.
• The 3-year median for Accumulated Depreciation & Amortization is $159925.0 (2019), against an average of $156458.7.
• Across the five-year window, Accumulated Depreciation & Amortization advanced 10.66% in 2019 and gained 3.13% in 2020, its largest moves.
• Akari Therapeutics' Accumulated Depreciation & Amortization stood at $144513.0 in 2018, then gained by 10.66% to $159925.0 in 2019, then gained by 3.13% to $164938.0 in 2020.
• The last three Accumulated Depreciation & Amortization figures came in at $164938.0 (Q4 2020), $159925.0 (Q4 2019), and $144513.0 (Q4 2018), per Business Quant data.